BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS

• Main Authors: BUNNAGE, MARK EDWARD, LOWE, MICHAEL DENNIS, LEE, ARTHUR, LOVERING, FRANK ELDRIDGE, PATNY, AKSHAY, SAIAH, EDDINE, ZAPF, CHRISTOPH WOLFGANG, PAPAIOANNOU, NIKOLAOS, LEE, KATHERINE LIN, PIERCE, BETSY SUSAN, VARGAS, RICHARD, TRZUPEK, JOHN DAVID, HAN, SEUNGIL, GOLDBERG, JOEL ADAM, HUANG, HORNGIH, HEPWORTH, DAVID, MATHIAS, JOHN PAUL, WANG, XIAOLUN, ANDERSON, DAVID RANDOLPH, STROHBACH, JOSEPH WALTER, GAVRIN, LORI KRIM, WRIGHT, STEPHEN WAYNE, CURRAN, KEVIN JOSEPH, DEHNHARDT, CHRISTOPH MARTIN
• Format: Patent
• Language: English
• Published: 25.08.2022
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. (Figure 2)